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Abstract: There has been an increase in the number of patients susceptible to invasive fungal 
infections (IFIs) leading to a greater need for effective, well tolerated, and easily administered 
antifungal agents. The advent of triazoles has revolutionized the care of patients requiring treat-
ment or prophylaxis for IFIs. However, triazoles have been associated with a number of adverse 
events and significant drug–drug interactions. While commonly used, physicians and patients 
should be aware of the distinct properties of these agents in order to ensure that patients are 
optimally treated with the least amount of toxicity possible. Clinicians should have a full under-
standing of the basic pharmacokinetics, absorption, and bioavailability of triazoles. Moreover, 
knowledge of the drug–drug interactions and potential toxicities of each agent is critical prior 
to administering a triazole. Careful history taking, thorough review of the patient’s medication 
list, and detailed discussion with the patients and their families about the efficacy, safety, and 
tolerability of these agents should be performed. Clinicians treating patients with triazoles should 
closely follow them, monitor pertinent laboratory tests, and consider measuring drug levels 
as needed. This article will review the basic pharmacokinetic properties and most frequently 
encountered adverse events and pitfalls associated with triazoles in clinical practice.
Keywords: triazoles, fluconazole, voriconazole, posaconazole, itraconazole, review, invasive 
fungal infections, adverse events, drug–drug interactions
Introduction
The increasing number of patients susceptible to invasive fungal infections (IFIs), 
including patients with hematologic malignancies and hematopoietic stem cell 
transplant (HSCT) recipients, has led to a greater need for effective, well tolerated, 
and easily administered antifungal agents.1–6 The advent of fluconazole in the early 
1990s revolutionized the treatment of IFIs caused by Candida species (eg, esophageal 
  candidiasis, candidemia).7–9 The relatively narrow spectrum of fluconazole activity and 
increasing frequency of invasive mold infections (IMIs) resulted in the development 
of the mold-active azoles, ie, itraconazole, voriconazole, and more recently, posacon-
azole. Azoles share certain properties that make them desirable options for patients 
who are being treated for IFIs. All are available as oral formulations, are usually well 
tolerated, and most of them can be administered once or twice daily. Although when 
compared with amphotericin B products, there is a lack of any serious nephrotoxicity 
or infusion-related reactions, triazoles have been associated with a number of adverse 
events and significant drug–drug interactions. Therefore, it is important to understand 
the metabolism and side effects of triazoles, to review any patient’s clinical history and 
medication list meticulously, and to monitor closely all patients treated with triazoles, Drug, Healthcare and Patient Safety 2010:2 28
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in order to ensure successful and safe outcomes. This review 
will focus on the safety and tolerability of the four triazoles 
most frequently used in clinical practice (fluconazole, itracon-
azole, voriconazole, and posaconazole) and those aspects of 
these antifungals that are associated with direct patient care. 
The microbiologic spectrum and major therapeutic indica-
tions of the triazoles is beyond the scope of this article and 
will not be discussed here.
Clinical pharmacology of triazole 
agents
Triazoles are synthetic compounds with a chemical structure 
comprising one or more five-membered azole rings that 
contain three nitrogen atoms. They have a higher affinity 
for fungal than mammalian target enzymes, which makes 
them less toxic, for instance, than imidazole compounds 
like ketoconazole and miconazole. The currently available 
systemic triazoles are fluconazole, itraconazole, voricon-
azole, and posaconazole. Ravuconazole, albaconazole, and 
isavuconazole are in advanced stages of clinical develop-
ment and will not be discussed in this article. In selecting 
the optimal triazole agent for therapy, it is important to 
consider not only its spectrum of activity, but also several 
other pharmacokinetic and pharmacodynamic parameters. 
There are limited data on pharmacodynamic properties of 
antifungal agents, but animal models suggest that killing of 
fungi with triazoles is optimized with maximal drug exposure 
over time (time-dependent killing).10–12 The pharmacokinetic 
properties of triazoles, which include absorption, distribution, 
metabolism, and excretion, will be reviewed herein and are 
summarized in Table 1.
Fluconazole
Fluconazole was the first triazole available on the market and 
was approved by the Food and Drug Administration (FDA) 
in 1990. It is available in both intravenous (IV) and oral (PO) 
formulations (tablets and suspension) and has similar pharma-
cokinetic properties when administered by both routes. Fol-
lowing oral administration, fluconazole is very well absorbed 
with an absolute bioavailability of 90% when measured in 
normal volunteers.13 Absorption of orally administered flu-
conazole is not affected by food or gastric pH.14 Peak plasma 
concentration occurs one to two hours after oral administra-
tion and a steady state is reached within five to 10 days.13 A 
loading dose (achieved by doubling the dose on the first day), 
can result in an increase in plasma concentrations nearing 
steady state within two days.13 Fluconazole has a volume of 
distribution that approximates that of total body water and also 
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when administered with food, especially with a high-fat meal 
and can be further enhanced by increasing the frequency of 
administration of the drug rather than the quantity of the 
administered dose.21–24 Peak plasma concentrations are attained 
within three to five hours after each oral administration and 
steady-state plasma concentrations are achieved within seven 
to 10 days with a regular dosing schedule. Posaconazole 
has a large volume of distribution, suggesting extensive 
tissue distribution. Limited data suggest that posaconazole 
has variable CSF penetration, ranging from undetectable to 
237%; no data are available on posaconazole penetration into 
the vitreous body.25,26 It is primarily metabolized in the liver 
through glucuronidation to biologically inactive metabolites 
and is predominantly eliminated in the feces.
Therapeutic perspectives  
and practical implications
The triazoles are a class of antifungal medications with 
significant adverse events, drug–drug interactions, and 
potentially variable serum concentrations. Basic concepts and 
common pitfalls associated with dosing, administration, and 
absorption of triazoles will be reviewed in this section.
Dosing of triazoles
Selection of the optimum dose of triazoles can be challeng-
ing because of the variable pharmacokinetics, absorption, 
and drug–drug interactions that these antifungals exhibit. 
Available data suggest that more than one-third of patients 
with candidemia may receive inadequate therapeutic dosing 
of fluconazole.27,28 Important considerations with triazole 
dosing include administration of a loading dose, dose adjust-
ment in patients with renal or hepatic dysfunction, and dose 
adjustment in the presence of concomitant medications with 
potential drug–drug interactions. In order to attain more 
rapid therapeutic concentrations close to steady state, current 
guidelines recommend administering a loading dose of the 
triazole being used.29,30 There are some data suggesting that 
clinicians occasionally neglect to use loading doses when 
prescribing a triazole.27,28,31 The duration of administration 
of the loading doses varies according to the antifungal agent 
used. The duration for fluconazole and voriconazole is the 
first 24 hours, for itraconazole the first three days, and for 
posaconazole the first seven days.
Fluconazole is minimally metabolized and 80% of the 
drug is excreted unchanged in the urine and, for that reason, is 
the only azole that needs to be dose-adjusted in patients with 
impaired renal function.13 In contrast, voriconazole is metabo-
lized by the liver and there is no need for dose-adjustment in 
has very low protein-binding which allows more free drug to 
be available. It has excellent tissue and body fluid penetration 
and achieves good concentration in the cerebrospinal fluid 
(CSF) and the vitreous humor. Hepatic metabolism plays 
a minimal role in the elimination of fluconazole, which is 
primarily cleared via the kidneys, with approximately 80% 
of the drug appearing unchanged in the urine.13
Itraconazole
Itraconazole is currently only available in capsule form and as 
a cyclodextrin itraconazole oral suspension, because the 
IV formulation has been withdrawn from the US market. 
The absorption of itraconazole is significantly impacted by 
the gastric pH, and peak plasma concentrations can be reached 
within one to four hours and a steady state within seven to 
14 days in normal, healthy volunteers. Itraconazole has a high 
  volume of distribution, is highly lipophilic, and has very good 
distribution in various tissues including lung, liver, esophagus, 
and stomach. Itraconazole is primarily metabolized via the 
cytochrome P450 (CYP450) system’s 3A4 isoenzyme, and 
its major active metabolite is hydroxyl-itraconazole.15 Itra-
conazole and its active metabolite are heavily protein bound 
(95%), hence their penetration into the CSF is minimal 
(1%). One pharmacokinetic study suggests that itraconazole 
may undergo saturable metabolism with multiple dosing.16
Voriconazole
Voriconazole is available as both an IV (solubilized in cyclo-
dextrin) and oral formulations (tablets and suspension). It is 
58% protein-bound, with a large volume of distribution of 
approximately 4.6 L/kg, suggesting extensive distribution into 
the tissues. Voriconazole penetrates well into the CSF, vitreous, 
and aqueous, with respective concentrations in these compart-
ments of 50%, 38.1%, and 53% the concentration found in 
plasma.17,18 Voriconazole is metabolized in the liver, predomi-
nately via the CYP2C19 isoenzyme and to a smaller degree by 
CYP2C9 and CYP3A4. Its major metabolite, N-oxide, does 
not appear to have any significant antifungal activity.19 Notably, 
voriconazole exhibits nonlinear pharmacokinetics due to satu-
ration of its metabolism and therefore a proportional increase in 
plasma levels is not achieved by simply increasing the dose.20 
Administering a loading dose however, may allow approximate 
plasma concentrations closer to steady state within one day in 
comparison to five or six days without a loading dose.19
Posaconazole
Posaconazole is currently only available as a suspension for 
oral administration. Bioavailability is significantly increased Drug, Healthcare and Patient Safety 2010:2 30
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patients with renal impairment, because only 2% of voricon-
azole is excreted in the urine. In patients with mild to moder-
ate hepatic impairment, voriconazole should be dose-adjusted 
using the Child-Pugh scoring system.19 Special note should 
be made to avoid the administration of IV voriconazole in 
patients with renal impairment (creatinine clearance 50 mL/
min), because of the potential accumulation of cyclodextrin, 
the solubilizing vehicle contained in this formulation.19
Voriconazole and CYP polymorphisms
Voriconazole is metabolized primarily by the CYP2C19 
enzyme. The CYP2C19 allele exhibits genetic polymor-
phism, resulting in three different phenotypes in patients, 
ie, homozygous-poor metabolizers, homozygous-extensive 
metabolizers, and heterozygous-intermediate metabolizers. 
Significant genetic variability in CYP2C19 has been reported 
and 15–20% of Asians and 2% of Caucasians have been 
found to be homozygous-poor enzyme metabolizers, which 
is associated with higher levels of voriconazole due to slower 
metabolism.32–34 A number of patients have also been found 
to be heterozygous for the CYP2C19 allele, which can be 
associated with moderately higher voriconazole levels than 
expected.34 Even though there are no current guidelines 
for routine testing of the CYP2C19 allele among patients 
treated with voriconazole in order to follow drug levels, 
clinicians should closely monitor their patients for potential 
voriconazole-associated toxicities, in particular, patients of 
Asian descent.
Weight considerations
Limited data exist on dosing of triazoles in obese patients 
(body mass index 30). Weight-based dosing, in mg/kg of 
fluconazole in obese patients should be used because there 
is an increase in clearance of fluconazole in this patient 
category, possibly as a result of the higher volume of 
  distribution.35 There are no data on pharmacokinetics and 
dosing of itraconazole, voriconazole, and posaconazole in 
obese patients.
Administration and absorption  
of triazoles
Ingestion or lack of food and other substances can signifi-
cantly affect the absorption and efficacy of certain triazoles. 
Fluconazole is the only triazole whose absorption is not 
affected by food or by gastric pH. In contrast, itraconazole 
has varied absorption patterns depending on the formulation 
prescribed. Itraconazole suspension is better absorbed on an 
empty stomach and absorption may decrease by up to 40% 
if taken with nonfatty meals.14,15,36,37 Itraconazole capsules 
require an acidic gastric pH and hence should be admin-
istered with food.15,38 Coadministration with cola products 
or cranberry juice increases absorption and should be dis-
cussed with patients in an effort to enhance compliance and 
efficacy. Proton pump inhibitors, H2 blockers, and antacids 
may compromise the absorption of itraconazole capsules due 
to gastric acidity reduction. In patients who require gastric 
protection, itraconazole capsule should not be prescribed 
and other options should be considered. The absorption of 
voriconazole may be reduced by 20%–30% when taken with 
food and, therefore, administration of voriconazole on an 
empty stomach or at least one hour before food is recom-
mended. Data suggest that coadministration with omeprazole 
may increase the area under the curve of voriconazole by 
40%.39 Posaconazole is available only as an oral formulation 
and bioavailability depends on coadministration with meals 
and frequency of dosing.22,23 Studies in healthy volunteers 
have shown that administration of posaconazole with food, 
and especially a high-fat meal, increase drug absorption.40,41 
Mean increases of up to 400% and 264% have been measured 
when given with a high-fat and low-fat meal, respectively, 
in comparison with the area under the curve of the drug 
when in the fasting state.40,41 Gastric pH does not appear 
to affect the absorption of this agent, although some data 
suggest that coadministration with cimetidine or a proton 
pump inhibitor (eg, omeprazole) may be associated with 
decreased levels.40,42–44
Limited data exist regarding the absorption of triazoles 
in patients with impaired gastrointestinal mucosal integrity 
resulting from chemotherapy-induced mucositis or graft ver-
sus host disease (GVHD). This is pertinent for patients with 
hematologic malignancies and HSCT recipients, because 
the presence of mucositis or GVHD of the gastrointestinal 
tract may lead to variable absorption and inadequate plasma 
concentrations of the administered triazole. In a sub-analysis 
of a prospective randomized study comparing posaconazole 
at 200 mg orally three times daily with fluconazole for anti-
fungal prophylaxis among allogeneic HSCT recipients with 
GVHD, patients with acute GVHD or/and diarrhea had lower 
plasma concentrations of posaconazole.45,46 Posaconazole 
levels appeared to be lower in five patients who developed a 
breakthrough IFI compared with patients who did not develop 
an IFI.45,46 The potential effect of gastrointestinal GVHD 
or mucositis, occasional difficulty of coadministration of 
posaconazole with meals, and active diarrhea or vomiting 
should prompt careful monitoring of these patients, includ-
ing monitoring of drug levels in order to ensure adequate Drug, Healthcare and Patient Safety 2010:2 31
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coverage.47 These data underscore the importance of close 
communication between the clinician and those patients 
treated with posaconazole.
Little is known about other routes of administration of 
the triazoles. Certain patient categories, for instance critically 
ill patients in the intensive care unit or patients with severe 
mucositis, may require administration of medications via a 
nasogastric tube (NGT). In addition, an increasing number 
of patients are discharged with an NGT or a percutaneous 
endoscopic gastrostomy (PEG) tube. At present, there is a 
paucity of data about the absorption of triazoles through 
an NGT or PEG tube to guide therapeutic decisions.48–52 
  Coadministration of a single dose of 400 mg of posaconazole 
with a nutritional supplement via an NGT in healthy 
  volunteers was associated with lower concentrations of the 
drug up to 20% compared with oral administration, in a 
Phase 1, open-label, single-center, randomized, crossover 
study.52 Intersubject variability was observed and issues, such 
as posaconazole absorption in sick NGT-fed patients and 
concentrations following routine loading doses of posacon-
azole, were not addressed.52 While more data are required, it 
appears that posaconazole suspension may be administered 
via an NGT with nutritional supplements and close plasma 
level monitoring for dose adjustment.
Other instances that may be associated with poor absorp-
tion of mold-active triazoles, especially of posaconazole, are 
when treating patients with cystic fibrosis because a lack of 
pancreatic enzymes can potentially decrease the absorption 
of the triazole. In an observational study of 35 lung transplant 
recipients with cystic fibrosis treated with voriconazole, 
plasma concentrations higher than 0.5 mg/L were attained 
in only 20% of the patients and administration of higher 
doses of voriconazole, IV administration of the drug, and/or 
concomitant use of other antifungal agents were required in 
a number of patients to attain the same efficacy.53 Consulta-
tion with an infectious diseases specialist should be sought 
in order to ensure that therapeutic levels will be attained if 
administration of other antifungal agents is not possible and 
treatment with posaconazole cannot be avoided. Careful 
review of each case individually should be performed before 
definitive recommendations can be given.
Pregnancy
Limited data exist on the use of triazoles in pregnant women, 
however all triazoles have been found to be teratogenic in 
animal studies.13,15,19,21 Moreover, prolonged administration of 
fluconazole in pregnant women has been associated with con-
genital abnormalities.54,55 However, several studies suggest 
that short courses of fluconazole in pregnant women may not 
lead to a higher risk for congenital malformation.54,56,57 Fur-
thermore, animal models suggest that fluconazole-associated 
teratogenicity may be dose-related.58 Data on itraconazole 
safety during pregnancy in humans is limited to two prospec-
tive European cohort studies which did not show increased 
risk for major congenital abnormalities.59,60 However, rates 
of spontaneous and induced abortion were higher in women 
who received itraconazole in one study.60 There are no 
human studies of voriconazole and posaconazole safety 
during pregnancy to the date. Fluconazole, itraconazole, and 
posaconazole are labelled as pregnancy category C medica-
tions and should not be used in pregnant women unless the 
benefit outweighs the risk, while voriconazole belongs to 
pregnancy category D medications and is contraindicated in 
pregnant women.13,15,19,21 Due to the limited data on the effect 
of triazoles when nursing, their administration is not recom-
mended for nursing mothers unless the benefit to the mother 
outweighs the potential risk to the infant.13,15,19,21
Drug–drug interactions
All triazoles exhibit some degree of drug–drug interactions 
due to their metabolism by the CYP450 system, as they can 
be substrates, inducers, and inhibitors of CYP enzymes, 
and coadministration with other agents that interfere with 
the CYP450 system may result in significant alteration of 
plasma triazole levels. P-glycoprotein is a transporter protein 
involved in the absorption and distribution of triazoles. 
Triazoles can function as substrates for P-glycoprotein 
and/or inhibitors, thus creating drug–drug interactions with 
other agents that also interact with this protein. It is crucial 
for clinicians to understand the mechanisms and potential 
drug–drug interactions with each triazole. Voriconazole 
and itraconazole appear to be more potent inhibitors of 
CYP450 compared with fluconazole and posaconazole.61 
Fluconazole is a substrate of CYP3A4 and inhibitor of 
CYP2C9 and 2C19, and its interactions with other agents 
often appear to be dose-dependent. Itraconazole and its 
major metabolite, hydroxyl-itraconazole, are substrates 
and inhibitors of CYP3A4. Additionally, itraconazole is a 
substrate and inhibitor of the P-glycoprotein. Voriconazole 
is both a substrate and inhibitor of CYP2C19, CYP2C9, 
and CYP3A4, with highest affinity for CYP2C19, fol-
lowed by CYP2C9. Its major metabolite N-oxide inhibits 
CYP3A4 and CYP2C9 to a greater extent than CPY2C19. 
Posaconazole is metabolized via the uridine diphosphate 
glucuronidation pathway; it is a substrate and inhibitor of 
the P-glycoprotein and a CYP3A4 inhibitor. There are a Drug, Healthcare and Patient Safety 2010:2 32
Neofytos et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
significant number of clinically important drug interactions 
that occur with all triazoles and careful consideration should 
be given when these agents are added to or discontinued 
from a patient’s drug regimen because adjustment of doses 
of the remaining medications may be necessary. Complete 
review of CYP450 mediated drug interactions with triazoles 
is beyond the scope of this article and key interactions are 
summarized in Table 2.
Major adverse events: Patient 
tolerability and compliance
The following section will discuss the major adverse events 
and impact of triazoles on patients’ activities of daily living 
and quality of life. Hepatotoxicity will be reviewed as an 
overall adverse event, rather than individually with each 
agent, as all triazoles may have an effect on liver function. 
Special consideration will be given to voriconazole because 
of its more complicated adverse event profile.
Hepatotoxicity
All triazoles have been associated with some degree of 
hepatotoxicity, ranging from mild hepatitis to cholestasis 
and, rarely, fulminant hepatic failure.13,15,19,21 Although not 
entirely clear, it appears that liver toxicity may be related 
to higher plasma drug levels, with most data coming from 
patients treated with voriconazole (abnormal liver tests 
between 2.9% and 33.3%, Table 3). There are no definitive 
guidelines to help clinicians decide when and how often to 
check liver tests and when it is appropriate to discontinue 
treatment due to hepatic impairment. Physicians should 
monitor liver function tests in patients taking triazoles during 
the first couple of weeks of treatment. Further decisions in 
case of abnormal results should be made based on critical 
assessment of each case individually and in consultation with 
an infectious diseases specialist. Because liver toxicity can 
have many potential causes in a subset of patients requiring 
treatment with a triazole, including comorbid conditions and 
treatment with other potentially hepatotoxic medications, 
clinicians should concomitantly investigate other causes of 
hepatic impairment.
Fluconazole
In addition to potential hetatotoxicity, patients treated with 
fluconazole may develop alopecia. In a review of patients 
treated with fluconazole alopecia was reported in up to 
12.5% to 20% of cases; the vast majority of patients received 
400 mg of fluconazole for a mean of 7.1 months.62 Alopecia 
most commonly occurs after prolonged treatment courses 
(median of three months in one study) and it may be subtle, 
starting indolently, and even go unnoticed initially.62 Exten-
sive hair loss requiring use of a wig has been reported in 
a small number of patients.62 In one review, alopecia was 
reversible within six months upon discontinuation of therapy 
with fluconazole or reduction of the dose by at least 50%.62 
Patients on prolonged treatment courses with fluconazole 
should be counselled accordingly and asked about hair loss 
during followup visits.
Itraconazole
Gastrointestinal symptoms, including nausea, vomiting, and 
diarrhea, are the most prominent and commonly reported 
side effects observed in patients treated with itraconazole. 
This is more common when itraconazole oral solution is 
used, predominantly as a result of the cyclodextrin vehicle 
used in this formulation. Although itraconazole solution 
is better absorbed than the capsule, gastrointestinal tox-
icity may significantly decrease patient compliance, and 
changing to the capsule form may be necessary. Two rare, 
but significant, side effects of itraconazole must also be 
discussed. Congestive heart failure, likely due to a direct 
negative inotropic effect of the drug, has led to a “black 
box” warning for itraconazole and treating physicians 
should thoroughly review their patients’ medical condi-
tions and medication list prior to prescribing this agent.63 
An aldosterone-like effect leading to hypokalemia, hyper-
tension, and occasionally peripheral edema has also been 
associated with itraconazole use, so careful electrolyte 
monitoring is warranted.64
Voriconazole
Visual changes
Visual changes in patients treated with voriconazole range 
from 4.0% to 44.8% (Table 3).65–71 Symptoms vary and 
include enhanced light perception, blurred vision, wavy 
or zigzag lines, increased “brightness” perception, altered 
visual or color perception, or photophobia.71,72 These are 
transient effects that occur shortly after administration of the 
drug, primarily observed with the first infusion, and tend to 
fade with subsequent infusions.68,71 In the vast majority of 
patients these visual changes do not require any interventions 
or discontinuation of the administered drug.67,68,71 However, 
dose adjustment may be required because recent data sug-
gest an association between voriconazole levels and visual 
adverse events.73 Patients and their families should be made 
aware of the various “visual effects” of voriconazole and 
patients cautioned about their ability to drive, particularly Drug, Healthcare and Patient Safety 2010:2 33
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Table 2 Summary of major documented and potential drug–drug interactions of triazoles*
Type of interaction and agent involved Triazole Recommendation
Decrease triazole plasma concentrations
Rifampin VOR, ITR, FLU, POS Contraindicated with VOR, monitor ITR levels,  
consider increasing FLU dose
High dose ritonavir (400 mg BID), St John’s wort VOR Contraindicated
Carbamazepine, long-acting barbiturates (eg, phenobarbital) VOR, ITR Contraindicated with VOR, monitor ADE and  
levels with ITR
Low-dose ritonavir (100 mg BID) VOR Avoid combination
Cimetidine, efavirenz POS Avoid combination
Esomeprazole, metoclopramide POS Monitor POS levels and breakthrough  
infections
Phenytoin, nevirapine ITR Monitor ITR levels and breakthrough  
infections
Plasma concentrations increased by triazole
Levacetylmethadol ITR Contraindicated
Astemizole, terfenadine VOR, FLU Contraindicated with VOR, FLU  400 mg  
is contraindicated with terfenadine,  
monitor ADE
Cisapride VOR, POS, ITR FLU Contraindicated
Pimozide, ergot alkaloids (eg, ergotamine) VOR, POS, ITR Contraindicated
Quinidine, dofetilide VOR, POS, ITR Quinidine contraindicated, dofetilide  
contraindicated only with ITR
Sirolimus VOR, POS, ITR Contraindicated with VOR, POS; monitor levels  
and ADE with ITR
Tacrolimus, cyclosporine VOR, POS, ITR, FLU Reduce dose, monitor levels
Methadone, short-acting opioids (eg, sufentanil), VOR Monitor ADE, dose reduction may be needed
Warfarin VOR, ITR, FLU Monitor PT, INR levels
Digoxin ITR Monitor ADE
Theophylline FLU Monitor theophylline levels
Plasma concentrations potentially increased by triazole
Benzodiazepines VOR, ITR, FLU Triazolam, oral midazolam are  
contraindicated with ITR; monitor  
ADE, consider dose reduction
Statins VOR, ITR Lovastatin, simvastatin are contraindicated  with 
ITR; monitor ADE, consider dose  reduction
Calcium channel blockers VOR, POS, ITR Nisoldipine is contraindicated with ITR, monitor   
ADE with other agents
Oral hypoglycemic, vinca alkaloids VOR, POS, ITR, FLU Monitor ADE
Other NNRTIs, other protease inhibitors VOR, POS, ITR Monitor ADE
Disopyramide ITR Monitor QTc interval, other ADE
Two-way interactions
Rifabutin VOR, POS, ITR Contraindicated with VOR, avoid combination 
with POS, ITR
Efavirenz VOR Increase VOR dose, reduce efavirenz dose
Phenytoin VOR, POS Increase VOR dose, monitor phenytoin  
levels and ADE
Omeprazole VOR Reduce omeprazole dose to ½ if 40 mg/day
Oral contraceptives VOR Monitor for ADE of both agents  
and voriconazole levels
Notes: *Table adjusted based on.13,15,19,21 
Abbreviations: BID, twice daily; FLU, fluconazole; ITR, itraconazole; VOR, voriconazole; POS, posaconazole; ADE, adverse events; PT, prothrombin time; INR, International 
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in the dark. Professional drivers, patients that drive to work, 
those that use computers or screens, and/or work during the 
night should be further educated and advised to seek medical 
attention as needed.
Central nervous system toxicity
Although poorly described, rates of visual hallucinations 
range from 4.3 to 6.7%.74 Interestingly, the majority of 
patients seem to be aware of these symptoms, frequently 
finding them pleasant.74 Amongst others, descriptions of 
these visual hallucinations have included “objects crawling 
on the wall” and “people being in the room”.74 Other CNS 
symptoms, including auditory hallucinations, confusion, 
hypotonia, irritability, and agitation have been reported in 
patients taking voriconazole.74,75 These symptoms appear 
to be dose-related and tend to present after one week of 
treatment (range 3–30 days in one study).39,75 Neurotoxicity 
has been associated with increased levels of voriconazole 
(plasma troughs 5.5 mg/L).39,75 Given that a number of 
patients requiring treatment with voriconazole may also 
be on psychotropic drugs or at risk for CNS infections 
that may present with hallucinations or confusion, making 
the diagnostic distinction can be difficult. Such symptoms 
should always be investigated and while voriconazole toxicity 
should be included in the differential diagnosis, all efforts 
should be made to rule out any other potential causes of these 
symptoms (eg, infectious meningo-encephalitis, other drug 
toxicities, etc.).
Skin reactions
A brief review of the major voriconazole clinical trials 
reveals an incidence of skin rash among patients receiv-
ing voriconazole ranging from 2.2% to 35.9%.68–71,76,77 
Skin reactions can present as a facial erythema, pruritus, 
hyperpigmentation, pseudoporphyria, or cheilitis.71,72,78–83 
Reactions can be mild to severe, but discontinuation of 
voriconazole due to a severe skin reaction has rarely been 
reported.71 An increasing number of patients receive vori-
conazole for extended periods of time whilst performing 
daily activities in their communities, hence photosensitivity 
reactions may increase. Moreover, there have been reports 
of cases of skin cancer with sun exposure in patients taking 
voriconazole.84 Because use of sunscreen appears to have 
some protective effect, clinicians should make appropriate 
recommendations to their patients and be vigilant about 
this infrequent adverse event.85 It is advised that patients, 
particularly children, who spend a significant part of their 
day outside, should be made aware of this side effect, wear 
sunscreen, and use long-sleeved shirts if possible. In cases 
of severe photosensitivity reactions, other agents should 
be considered, and close monitoring and followup of these 
patients reinforced.
Table 3 Review of major studies reporting on adverse events associated with voriconazole
Study n Patient population Indication Nausea Chills Fever Visual  
hallucinations
Visual  
changes
Liver  
enzymes
Rash
65 200 Immunocompromised  
hosts
Esophageal  
candidiasis
6% NR 12% NR 23% 6.5%1 5.5%
68 415 Heme malignancy,  
solid tumor, HSCT
Neutropenic  
fever
9.4% 13.7% NR 4.3% 21.9% 2.9%–8.9%2 3.4%3
70 194 Heme malignancy,  
HSCT/SOT
IA NR 3.1%4 3.1%4 6.7% 44.8% 3.6% 8.2%
71 137 Heme malignancy,  
HSCT/SOT, DM, HIV
IA 2.2% NR NR NR 10.9% 14.6%5 8.8%
96 45 Heme malignancy,  
HSCT/SOT
IMI 2.2% NR NR NR NR 8.9% 2.2%
66 52 Heme malignancy,  
SOT, HIV, other6
IC 25% NR NR NR 21.2% 23%7 15.4%
69 272 NR IC NR 3% 15% NR 4% 23% 6%
67 39 Heme malignancy,  
HSCT/SOT, other
IA, CPA NR NR NR NR 30.8%8 33.3% 35.9%9
Notes: 1Elevation of alkaline phosphatase only reported; 2Including together elevation of transaminases and alkaline phosphatase 5 × the baseline value; 3flushing; 4rates 
for chills and fevers reported together; 53–5 × upper normal limit; 6other, chronic obstructive pulmonary disease, tuberculosis, bronchiectasis, diabetes mellitus, alcoholism; 
7predominantly elevated transaminases; 8visual changes defined as: enhanced light perception, photophobia, color vision changes, blurred vision, and wavy lines on television or 
on going to sleep; 9rash in 6 patients, photosensitivity in 3 patients, and cheilitis in 5 patients.
Abbreviations: n, number of patients; NR, not reported; heme, hematologic; HIV, human immunodeficiency virus; HSCT, hematopoietic stem cell transplant; SOT, solid organ 
transplant; IA, invasive aspergillosis; DM, diabetes mellitus; IMI, invasive mold infection; IC, invasive candidiasis; CPA, chronic pulmonary aspergillosis.Drug, Healthcare and Patient Safety 2010:2 35
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Posaconazole
The most commonly reported side effects related to 
posaconazole include nausea (5%–17.4%) and vomiting 
(4%–8.7%) (Table 4).45,86–88 Because erratic absorption of 
this agent is one of its major limitations, patients should 
be carefully monitored and routinely interviewed about 
possible gastrointestinal complaints that could further 
compromise the absorption and efficacy of the drug. 
A potentially significant, albeit rare (1%–5%) side effect is 
QTc prolongation and torsades de pointes (Table 4). Careful 
review of the patient’s medication list should be performed 
and posaconazole should be avoided in the presence of 
concomitantly administered agents with potential effect 
on the QTc interval.
Therapeutic drug level monitoring
With the exception of itraconazole, there are no definitive 
recommendations for therapeutic drug monitoring for other 
triazoles.89 Fluconazole, due to its linear pharmacokinetics and 
its long clinical experience, does not require therapeutic drug 
monitoring. In the case of itraconazole, therapeutic drug moni-
toring is suggested one to two weeks after treatment initiation 
to ensure therapeutic levels.89,90 Using high-performance liquid 
chromatography (HPLC), plasma levels for itraconazole and 
hydroxyl-itraconazole can be accurately measured. Although 
the therapeutic itraconazole concentration range has not 
been defined as yet, a random itraconazole level of at least 
1.0 µg/mL is recommended for the treatment of histoplasmo-
sis.90 Posaconazole has a long half-life and although it may take 
up to 100 hours to reach a steady state, adequate therapeutic 
levels may be attained within one to two days.91 Posaconazole 
peak and average concentrations of 1.50 mg/L and 1.25 mg/L, 
respectively, have been associated with 75% response rates.88 
However, very limited data on posaconazole levels are available 
to date, and these do not allow for any meaningful conclusions. 
Expert recommendations include measuring posaconazole 
levels in patients with mucositis, gastrointestinal GVHD, and 
those with concerns of decreased absorption.46,47
Multiple reports have underscored the variability of 
voriconazole plasma levels.39,92–94 In a review of HSCT 
  recipients receiving standard voriconazole doses, plasma 
trough voriconazole levels were undetectable in 15% of 
patients.95 Limited data from uncontrolled studies, most of 
them retrospective, in different patient populations, and mea-
suring random or trough plasma voriconazole levels show that 
trough levels of voriconazole 1 µg/mL may be associated 
with improved outcomes.39,73,75,93–95 Higher voriconazole 
levels have been associated with visual adverse events, neuro-
logic toxicities, and elevated aspartate aminotransferase and 
alkaline phosphatase.39,73,75 Despite the possible limitations of 
Table 4 Review of major studies reporting on adverse events associated with posaconazole
Study n Patient  
population
Dose Nausea Vomiting Headache Dizziness QT  
prolongation
Rash Liver  
enzymes
AST ALT ALP
97 448 Healthy  
volunteers
50–1200  
mg/d
NR NR 17% 6% None NR NR 6% 11% NR
87 330 Cancer,  
HSCT
800 mg/d 14% 6% 5% 5% 5% NR NR 5% NR 5%
86 23 SOT 800 mg/d 17.4% 8.7% NR NR NR NR NR 8.7% 4.3% NR
98 53 Heme,  
HSCT
800 mg/d NR NR NR NR NR NR NR 0 NR 0
88 107 Cancer,  
HSCT/SOT,  
other1
800 mg/d 12% 5% 3% 3% 0 4% 3% NR 2% NR
99 304 AML/MDS 600 mg/d NR NR NR NR 1% NR 1% NR 1% NR
45 301 HSCT 600 mg/d 7% 4% 1% NR NR NR 3% 3% 3% NR
100 428 Cancer,  
HSCT/SOT,  
other2
800–1200  
mg/d
8% 7% 9% 2% 2% 3% 2% 3% 5% NR
101 21 Cancer,  
HSCT/SOT,  
DM
800 mg/d 5% 5% NR NR 0 5% NR 5% NR NR
Notes: 1Other, diabetes mellitus, HIV/AIDS; 2Other, acquired immunocompromising conditions, no known underlying immunocompromising conditions.
Abbreviations: n, number of patients; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; d, day; NR, not reported; heme, hematologic 
malignancy; HSCT, hematopoietic stem cell transplant; SOT, solid organ transplant; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; DM, diabetes mellitus.Drug, Healthcare and Patient Safety 2010:2 36
Neofytos et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
these studies, suggested target plasma voriconazole trough 
levels are between 1.0 and 5.5 µg/mL.39 More prospective 
data are required to make definitive recommendations, and 
clinicians should consider obtaining plasma voriconazole lev-
els in patients who appear not to respond to treatment, those 
with significant drug–drug interactions, and with evidence 
of voriconazole-associated toxicities.
Conclusions
The advent of triazoles has revolutionized the care of 
patients requiring treatment or prophylaxis for IFIs. While 
commonly used, physicians and patients should be aware 
of the distinct properties of these agents in order to ensure 
that patients are optimally treated with the least amount 
of toxicity possible. Favorable outcomes require critical 
assessment and selection of the appropriate therapeutic agent 
for each patient. This decision should be based on the type 
of infection treated, the patient category, and the efficacy 
and toxicities of the selected agent. Drug–drug interactions 
and the various side effects of triazoles can significantly 
impact patients’ lifestyle. Clinicians should have a full 
understanding of the basic pharmacokinetics, absorption, 
and bioavailability of these drugs. Moreover, knowledge of 
the drug–drug interactions and potential toxicities of each 
agent is critical prior to administering a triazole. Careful 
history taking, thorough review of the patient’s medica-
tion list, and detailed discussion with the patients and their 
families about the efficacy, safety, and tolerability of these 
agents should be performed. Clinicians treating patients 
with triazoles should closely follow them, monitor perti-
nent laboratory tests, and consider measuring drug levels 
as needed. Consultation with an infectious diseases expert 
should be sought if feasible.
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